SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-22-003167
Filing Date
2022-11-10
Accepted
2022-11-10 17:03:14
Documents
76
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tmb-20220930x10q.htm   iXBRL 10-Q 1942037
2 EX-31.1 tmb-20220930xex31d1.htm EX-31.1 14329
3 EX-32.1 tmb-20220930xex32d1.htm EX-32.1 7289
4 GRAPHIC tmb-20220930x10q001.jpg GRAPHIC 51952
  Complete submission text file 0001410578-22-003167.txt   8330736

Data Files

Seq Description Document Type Size
5 EX-101.SCH tmb-20220930.xsd EX-101.SCH 58498
6 EX-101.CAL tmb-20220930_cal.xml EX-101.CAL 49450
7 EX-101.DEF tmb-20220930_def.xml EX-101.DEF 299782
8 EX-101.LAB tmb-20220930_lab.xml EX-101.LAB 448969
9 EX-101.PRE tmb-20220930_pre.xml EX-101.PRE 425123
70 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20220930x10q_htm.xml XML 1409143
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

IRS No.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-12584 | Film No.: 221378353
SIC: 2834 Pharmaceutical Preparations